Spero Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 103.78 million compared to USD 53.51 million a year ago. Net income was USD 22.81 million compared to net loss of USD 46.42 million a year ago.

Basic earnings per share from continuing operations was USD 0.43 compared to basic loss per share from continuing operations of USD 1.23 a year ago. Diluted earnings per share from continuing operations was USD 0.43 compared to diluted loss per share from continuing operations of USD 1.23 a year ago.